![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1608839
¼¼°èÀÇ ´« ¿°Áõ Ä¡·á ½ÃÀå : ¾àÈ¿±ºº°, Á¦Çüº°, À¯Åëä³Îº°, Áö¿ªº° ½ÃÀå ÇöȲEye Inflammation Treatment Market, By Drug Class, By Dosage Form, By Distribution Channel, By Geography |
´« ¿°Áõ Ä¡·á ½ÃÀåÀº 2024³â 6¾ï 2,190¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. 2024³âºÎÅÍ 2031³â±îÁö 5.9%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» º¸À̸ç 2031³â¿¡´Â 9¾ï 2,680¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
º¸°í ¹üÀ§ | º¸°í¼ »ó¼¼³»¿ë | ||
---|---|---|---|
±âÁØ ¿¬µµ | 2023³â | 2024³â ½ÃÀå ±Ô¸ð | 6¾ï 2,190¸¸ ´Þ·¯ |
½ÇÀû µ¥ÀÌÅÍ | 2019-2023³â | ¿¹Ãø ±â°£ | 2024-2031³â |
¿¹Ãø ±â°£(2024-2031³â) CAGR: | 5.90% | 2031³â °¡Ä¡ ¿¹Ãø | 9¾ï 2,680¸¸ ´Þ·¯ |
´«ÀÇ ¿°ÁõÀº ´«º´À̶ó°íµµ Çϸç, ´«ÀÇ ºÎÁ¾°ú ¿°ÁõÀ» ¸»ÇÕ´Ï´Ù. ÀϹÝÀûÀ¸·Î °¨¿°, ¾Ë·¹¸£±â ¹× ±âŸ °Ç° »óÅ·ΠÀÎÇØ ¹ß»ýÇÕ´Ï´Ù. ¾ÈÁúȯ¿¡ Ãë¾àÇÑ ³ë·É Àα¸ Áõ°¡, Àü ¼¼°è °á¸·¿° ȯÀÚÀÇ À¯º´·ü Áõ°¡, ½ÅÁ¦Ç° Ãâ½Ã´Â ´« ¿°Áõ Ä¡·áÁ¦ ¹× ÀåÄ¡¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ãų ¼ö ÀÖ½À´Ï´Ù. ¾à¹° Àü´Þ ¹× ¼¹æÇü Á¦Á¦ÀÇ ¹ßÀüÀ¸·Î Ä¡·á È¿°ú¿Í ȯÀÚ ¼øÀÀµµ°¡ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. »õ·Î¿î Ä¡·á ¿É¼ÇÀÇ ³ôÀº ºñ¿ë°ú ºí·Ï¹ö½ºÅÍ ¾à¹°ÀÇ Æ¯Çã ¸¸·á´Â ½ÃÀå ¼ºÀå¿¡ °É¸²µ¹·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. »õ·Î¿î ¾à¹° ¹× ¾à¹°°ú ±â±âÀÇ º´¿ë¿ä¹ý¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ¿¬±¸°¡ ½ÃÀå ¼ºÀåÀÇ ±âȸ°¡ µÉ ¼ö ÀÖ½À´Ï´Ù.
´« ¿°Áõ Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀº °á¸·¿°, Æ÷µµ¸·¿°°ú °°Àº ¾È±¸ ¿°ÁõÀÇ À¯º´·ü Áõ°¡, ¾È±¸ °Ç°¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ¾Ë·¹¸£±â ¹× ÀÚ°¡¸é¿ª ÁúȯÀÇ ¹ß»ý·ü Áõ°¡, È¿´ÉÀÌ °³¼±µÈ ½Å¾àÀÇ Ãâ½Ã·Î ÀÎÇÑ °ÍÀ¸·Î ºÐ¼®µË´Ï´Ù. ±×·¯³ª »ý¹°ÇÐÀû Á¦Á¦ ¹× ¼¼Æ÷Ä¡·áÁ¦ÀÇ ³ôÀº ºñ¿ëÀº ½ÃÀå ¼ºÀå¿¡ °É¸²µ¹ÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ¾à¹°°ú ¾à¹° Àü´Þ ÀåÄ¡¸¦ Ȱ¿ëÇÑ º´¿ë¿ä¹ýÀÇ °³¹ß, ¹ÙÀÌ¿À½Ã¹Ð·¯ÀÇ µîÀå, ½ÅÈï±¹ ½ÃÀå¿¡¼ÀÇ È®´ë´Â ½ÃÀå ±â¾÷µé¿¡°Ô ¼ºÀå ±âȸ¸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù. ºí·Ï¹ö½ºÅÍ ÀǾàǰÀÇ Æ¯Çã ¸¸·á¿Í ¾È°ú¿ë ½ÅÁ¦Ç° ½ÂÀο¡ ´ëÇÑ ¾ö°ÝÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.
º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡
ÀÌ º¸°í¼´Â 2023³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© 2024-2031³â±îÁöÀÇ ¿¹Ãø ±â°£(2024-2031³â) ½ÃÀå ±Ô¸ð(USD Mn)¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR%)À» ÅëÇØ ¼¼°è ´« ¿°Áõ Ä¡·áÁ¦ ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇÕ´Ï´Ù.
¶ÇÇÑ, ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¼öÀÍ ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.
¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ Áß¿äÇÑ °í·Á»çÇ×µµ Á¦°øÇÕ´Ï´Ù.
¼¼°è ´« ¿°Áõ Ä¡·á ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏÀ» ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, ½ÇÀû, Àü·« µîÀÇ ¸Å°³º¯¼ö¸¦ ±âÁØÀ¸·Î Á¤¸®Çß½À´Ï´Ù.
ÀÌ Á¶»ç ´ë»ó ÁÖ¿ä ±â¾÷À¸·Î´Â GSK plc, Merck &Co.Inc, Alimera Sciences, Inc, AbbVie Inc, Teva Pharmaceutical Industries Ltd, Akron Pharma Inc. Pharmaceuticals Ltd., Mylan N.V., Amgen Inc., Pfizer Inc. µîÀÌ ÀÖ½À´Ï´Ù.
ÀÌ º¸°í¼ÀÇ ÅëÂû·ÂÀ» ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ, ½ÃÀå È®´ë ¹× ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
¼¼°è ´« ¿°Áõ Ä¡·á ½ÃÀå º¸°í¼´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ½ÃÀå ÁøÃâ±â¾÷, À繫 ºÐ¼®°¡ µî ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.
ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è ´« ¿°Áõ Ä¡·á ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ½±°Ô ³»¸± ¼ö ÀÖ½À´Ï´Ù.
Eye inflammation treatment market is estimated to be valued at USD 621.9 Mn in 2024 and is expected to reach USD 926.8 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 5.9% from 2024 to 2031.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2023 | Market Size in 2024: | 621.9 Mn |
Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 to 2031 |
Forecast Period 2024 to 2031 CAGR: | 5.90% | 2031 Value Projection: | 926.8 Mn |
Eye inflammation, also known as ophthalmia, refers to the swelling and irritation of the eyes. It is usually caused by infections, allergies or other medical conditions. Rising geriatric population susceptible to age-related ocular disorders, growing prevalence of conjunctivitis cases worldwide and new product launches can boost demand for eye inflammation drugs and devices. Advancements in drug delivery methods and sustained release formulations have improved treatment effectiveness and patient compliance. High costs of newer treatment options and patent expiries of blockbuster drugs pose challenges for the market growth. Ongoing research on novel drugs and drug-device combination therapies can offer market growth opportunities.
Eye inflammation treatment market growth is driven by growing prevalence of eye inflammations like conjunctivitis and uveitis, increasing incidence of allergies and autoimmune diseases affecting eye health, and launch of newer drugs with improved efficacy. However, high costs of biologics and cell therapy can hamper the market growth. Development of combination therapies utilizing drugs and drug delivery devices, emergence of biosimilars, and expansion in emerging economies can offer growth opportunities for market players. Patent expiries of blockbuster drugs and stringent regulatory framework for approval of new ophthalmic products can hamper the market growth.
Key features of the study
This report provides in-depth analysis of the global eye inflammation treatment market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global eye inflammation treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include GSK plc., Merck & Co. Inc., Alimera Sciences, Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Akron Pharma Inc., Intas Pharmaceuticals Ltd., Mylan N.V., Amgen Inc., Pfizer Inc., and Macleods Pharmaceuticals Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global eye inflammation treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global eye inflammation treatment market